Vista Exclusive Content
Breast Cancer Innovator Atossa Genetics Adds Former Pfizer & Boehringer Ingelheim Execs To New Strategic Advisory Board
Seattle based Atossa Genetics Inc. (ATOS) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. Today Atossa announced the formation of a strategic advisory board (SAB) comprised of prominent executives from the pharmaceutical industry. The
Learn More About The AACR Annual Meeting 2018: “Driving Innovative Cancer Science to Patient Care”
The mission of the American Association for Cancer Research (AACR) is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among
Pfizer Beats Street Reporting Q4 & Full-Year 2017 Earnings
Pfizer (PFE) reported earnings on 1/30/2018 of $0.62/share firmly beating estimates of $0.583 per share. Pfizer’s abbreviated notes are as follows: Full-Year 2017 Revenues of $52.5 Billion, Comparable with Full-Year 2016 Operationally; Excluding Impact of February 2017 Divestiture of Hospira Infusion Systems (HIS), Revenues Increased
Company News Around The Web
18 May 2018 | 7:21 pm
Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric...
Pfizer (PFE) announces positive top-line results from a phas...
18 May 2018 | 6:58 pm
Eli Lilly’s Valuation on May 17
Eli Lilly (LLY) reported EPS of $1.34 and revenues of $5.7 b...
18 May 2018 | 6:35 pm
Pharma Stock Roundup: Zoetis to Buy Abaxis,...
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approv...
18 May 2018 | 2:30 pm
Exelixis Is Focused on Management of the...
Exelixis (EXEL) is focused on the label expansion and life c...
18 May 2018 | 1:00 pm
Label Expansion May Boost Cabometyx’s Revenue in...
On January 16, Exelixis (EXEL) and Ipsen announced positive ...
18 May 2018 | 11:32 am
Cabometyx Is Expected to Witness a Robust...
In the first quarter, Exelixis’s (EXEL) Cabometyx witnesse...
|Day Low - High||-|
|Year Low - High||-|